The deal – which is worth up to $905 million with an upfront fee of $90 million – gives BMS full control of BridgeBio's experimental SHP2 inhibitor BBP-398, which is already in a phase 1 trial ...

Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows ...

We have submitted a New Drug Application (NDA) for the KRAS G12C inhibitor glecirasib and have licensed out the China rights of glecirasib and the SHP2 inhibitor sitneprotafib to our partner.